Skip to main content
. 2021 Aug 28;28(5):3331–3346. doi: 10.3390/curroncol28050289

Figure 3.

Figure 3

Supposed mechanisms of cardiovascular toxicity of androgen deprivation therapy (ADT) in patients with prostate cancer. Hypogonadism induced by ADT is involved in the occurrence of the cardiotoxicity by many mechanisms. The direct contribution of ADT is not obvious excepting CYP 17 inhibitors which indirectly induce a surge of mineralocorticosteroid secretion and GnRH agonists.